Skip to main content
. 2014 Apr 6;145(1):33–44. doi: 10.1007/s10549-014-2925-7

Fig. 4.

Fig. 4

Patient outcome with respect to HER2/HER3 and p21 status in HER2+ breast cancer treated with trastuzumab. Overall survival (a) and disease-free interval (b). HER2/HER3 + p21- (n = 13), Other groups: HER2/HER2 + p21 + , HER2/HER3- p21 + , HER2/HER3-p21- (n = 75). Time in months